Short Interest in Dyadic International Inc. (NASDAQ:DYAI) Declines By 36.6%

Dyadic International Inc. (NASDAQ:DYAI) was the target of a large decline in short interest in July. As of July 31st, there was short interest totaling 52,977 shares, a decline of 36.6% from the July 15th total of 83,534 shares. Approximately 0.2% of the company’s stock are short sold. Based on an average daily volume of 212,919 shares, the days-to-cover ratio is currently 0.2 days.

Analysts Set New Price Targets

Separately, Weiss Ratings raised shares of Dyadic International from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, August 12th. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $3.00.

Hedge Funds Weigh In On Dyadic International

Several hedge funds have recently made changes to their positions in DYAI. Bank of America Corp DE raised its stake in shares of Dyadic International by 16,146.7% during the 4th quarter. Bank of America Corp DE now owns 27,132 shares of the biotechnology company’s stock valued at $47,000 after purchasing an additional 26,965 shares during the period. Landscape Capital Management L.L.C. bought a new position in Dyadic International in the 3rd quarter worth about $190,000. Marathon Capital Management boosted its stake in Dyadic International by 142.9% in the 4th quarter. Marathon Capital Management now owns 85,000 shares of the biotechnology company’s stock worth $80,000 after purchasing an additional 50,000 shares during the period. Geode Capital Management LLC grew its holdings in Dyadic International by 13.7% during the 4th quarter. Geode Capital Management LLC now owns 301,673 shares of the biotechnology company’s stock valued at $284,000 after buying an additional 36,266 shares in the last quarter. Finally, BlackRock Inc. purchased a new position in Dyadic International during the 2nd quarter valued at about $177,000. 27.95% of the stock is currently owned by hedge funds and other institutional investors.

Dyadic International Stock Performance

NASDAQ DYAI opened at $0.74 on Thursday. The company has a debt-to-equity ratio of 4.08, a quick ratio of 1.65 and a current ratio of 1.65. The company has a market capitalization of $26.93 million, a PE ratio of -3.21 and a beta of 1.12. The company has a 50-day simple moving average of $0.97 and a 200 day simple moving average of $0.86. Dyadic International has a 52-week low of $0.65 and a 52-week high of $1.60.

Dyadic International (NASDAQ:DYAI) last posted its quarterly earnings results on Wednesday, August 12th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by ($0.02). The business had revenue of $0.96 million during the quarter, compared to the consensus estimate of $1.02 million. Dyadic International had a negative net margin of 201.43% and a negative return on equity of 2,920.31%. On average, research analysts predict that Dyadic International will post 0.13 EPS for the current year.

About Dyadic International

Dyadic International, Inc is a biotechnology company headquartered in Jupiter, Florida, that specializes in developing and commercializing its proprietary C1 fungal-based expression platform. The company’s core business revolves around enabling efficient, scalable production of proteins and enzymes for a wide range of applications, including biopharmaceuticals, industrial enzymes, agricultural bioactives and biofuels. By leveraging its C1 system, Dyadic seeks to offer clients cost-effective, high-yield manufacturing processes that can accelerate development timelines and reduce overall production costs.

The Dyadic C1 platform is designed to produce complex proteins five to ten times faster than traditional cell culture technologies, such as CHO cells or yeast.